Annika Bansal – Lifestyle
Author:
Upstream Bio
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
May 18, 2026
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
April 17, 2026
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
March 26, 2026
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
March 5, 2026
Upstream Bio to Participate in Upcoming March Investor Conferences
March 4, 2026